DOP2019000241A - ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS - Google Patents

ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS

Info

Publication number
DOP2019000241A
DOP2019000241A DO2019000241A DO2019000241A DOP2019000241A DO P2019000241 A DOP2019000241 A DO P2019000241A DO 2019000241 A DO2019000241 A DO 2019000241A DO 2019000241 A DO2019000241 A DO 2019000241A DO P2019000241 A DOP2019000241 A DO P2019000241A
Authority
DO
Dominican Republic
Prior art keywords
n3pglu
antibodies
beta amyloid
peptide beta
n3pglu antibodies
Prior art date
Application number
DO2019000241A
Other languages
English (en)
Inventor
Tang Ying
Lu Jirong
Bradley Demattos Ronald
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2019000241A publication Critical patent/DOP2019000241A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Abstract

Anticuerpos contra N3pGlu Aß humano, composiciones que comprenden tales anticuerpos N3pGlu Aß, y métodos de uso tales anticuerpos N3pGlu Aß para el tratamiento de una enfermedad caracterizada por la deposición de Aß que incluye la enfermedad de Alzheimer clínica o preclínica, síndrome de Down, y angiopatía amiloide cerebral clínica o preclínica.
DO2019000241A 2017-04-20 2019-09-20 ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS DOP2019000241A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
DOP2019000241A true DOP2019000241A (es) 2019-10-15

Family

ID=62111232

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000241A DOP2019000241A (es) 2017-04-20 2019-09-20 ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS

Country Status (28)

Country Link
US (3) US10647759B2 (es)
EP (1) EP3612559A1 (es)
JP (3) JP6900500B2 (es)
KR (2) KR102352670B1 (es)
CN (2) CN110582511B (es)
AR (1) AR111208A1 (es)
AU (2) AU2018255221B2 (es)
BR (1) BR112019018810A2 (es)
CA (1) CA3058482C (es)
CL (1) CL2019002922A1 (es)
CO (1) CO2019011349A2 (es)
CR (1) CR20190445A (es)
DO (1) DOP2019000241A (es)
EA (1) EA201992163A1 (es)
EC (1) ECSP19075146A (es)
IL (1) IL269003A (es)
JO (1) JOP20190247A1 (es)
MA (1) MA50144A (es)
MX (2) MX2019012445A (es)
NZ (1) NZ758066A (es)
PE (1) PE20200011A1 (es)
PH (1) PH12019502361A1 (es)
SA (1) SA519410311B1 (es)
SG (1) SG11201909022PA (es)
TW (2) TWI789644B (es)
UA (1) UA126806C2 (es)
WO (1) WO2018194951A1 (es)
ZA (1) ZA202007868B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
AU2020245031A1 (en) 2019-03-26 2021-10-21 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
KR20230061462A (ko) 2020-10-02 2023-05-08 일라이 릴리 앤드 캄파니 단백질 정제 공정에서의 숙주 세포 단백질 함량의 감소 방법
TW202243690A (zh) 2021-01-11 2022-11-16 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
CA3235104A1 (en) * 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
TW202334210A (zh) 2021-10-29 2023-09-01 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
TW202336034A (zh) * 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
WO2023076971A1 (en) 2021-10-29 2023-05-04 Eli Lilly Company Compounds and methods targeting interleukin-34
WO2023076970A1 (en) * 2021-10-29 2023-05-04 Eli Lilly And Company Compounds and methods targeting interleukin-34
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200202799T3 (tr) * 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
MY148086A (en) * 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CA2723995A1 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
WO2010004434A2 (en) 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
AU2009273387B9 (en) 2008-07-21 2015-06-11 Vivoryon Therapeutics N.V. Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
CN103068848B (zh) * 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
CN114773476A (zh) * 2015-04-13 2022-07-22 辉瑞公司 治疗性抗体和它们的用途
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
CL2019002922A1 (es) 2020-03-13
US10647759B2 (en) 2020-05-12
BR112019018810A2 (pt) 2020-05-05
KR20220011800A (ko) 2022-01-28
TW201902924A (zh) 2019-01-16
JP2021151253A (ja) 2021-09-30
AU2018255221B2 (en) 2021-07-01
AU2021203927A1 (en) 2021-07-08
EA201992163A1 (ru) 2020-03-02
US20200262902A1 (en) 2020-08-20
CN117024583A (zh) 2023-11-10
CN110582511B (zh) 2023-08-08
KR20190129100A (ko) 2019-11-19
WO2018194951A1 (en) 2018-10-25
ECSP19075146A (es) 2019-10-31
AR111208A1 (es) 2019-06-12
AU2018255221A1 (en) 2019-09-19
CO2019011349A2 (es) 2019-10-31
KR102352670B1 (ko) 2022-01-19
PH12019502361A1 (en) 2020-07-13
TW202120541A (zh) 2021-06-01
PE20200011A1 (es) 2020-01-06
JP2020510081A (ja) 2020-04-02
US20210371509A1 (en) 2021-12-02
AU2021203927B2 (en) 2024-03-21
MA50144A (fr) 2020-07-29
CA3058482C (en) 2023-05-09
MX2019012445A (es) 2020-01-13
CN110582511A (zh) 2019-12-17
JP2023058623A (ja) 2023-04-25
UA126806C2 (uk) 2023-02-08
KR102567295B1 (ko) 2023-08-16
SG11201909022PA (en) 2019-11-28
ZA202007868B (en) 2023-06-28
US11078261B2 (en) 2021-08-03
JP7227312B2 (ja) 2023-02-21
TWI789644B (zh) 2023-01-11
EP3612559A1 (en) 2020-02-26
CR20190445A (es) 2019-11-06
JOP20190247A1 (ar) 2019-10-20
IL269003A (en) 2019-10-31
CA3058482A1 (en) 2018-10-25
US20180305444A1 (en) 2018-10-25
MX2022011817A (es) 2022-10-10
JP6900500B2 (ja) 2021-07-07
NZ758066A (en) 2022-10-28
SA519410311B1 (ar) 2022-03-20
TWI705975B (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
DOP2019000241A (es) ANTICUERPOS ANTI-PÉPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
ECSP20081591A (es) Proteínas de fusión que comprenden progranulina
BR112018014281A2 (pt) agentes, usos e métodos para o tratamento da sinucleinopatia
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EA201692109A1 (ru) Варианты антител к фактору d и их применение
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
GB2582683B (en) Composition for the care of human hair
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
CL2018003013A1 (es) Uso de un inhibidor de la acetilcolinesterasa e idalopirdina para reducir las caídas en pacientes con la enfermedad de parkinson.
BR112017003200A2 (pt) anticorpos de potenciamento do fator h e seus usos
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
BR112022004475A2 (pt) Proteínas de fusão nkg2d e usos das mesmas
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales
ITUB20169928A1 (it) Formulazioni farmaceutiche per il trattamento del diabete